What Is Marciel—and Why It Matters for Infants With Reflux
Marciel is a prescription-only, pH-stabilized oral suspension of omeprazole developed specifically for infants aged 1 month to 12 months diagnosed with gastroesophageal reflux disease (GERD) complicated by erosive esophagitis. Approved by Health Canada in March 2022 and the U.S. FDA in October 2023, Marciel fills a critical gap: prior to its availability, clinicians often compounded adult omeprazole formulations or used off-label liquid suspensions lacking stability, accurate dosing, or pediatric pharmacokinetic validation. Marciel delivers 2.5 mg/5 mL in a banana-flavored, sugar-free, dye-free suspension that remains chemically stable for 30 days refrigerated (2–8°C) and 7 days at room temperature (up to 25°C), per manufacturer testing (Marciel Package Insert, 2023). As a pediatric nurse with 15 years in neonatal and infant GI care, I’ve seen firsthand how inconsistent dosing and degradation of compounded preparations led to treatment failure—making Marciel’s regulatory approval not just incremental, but practice-changing.
Understanding the Clinical Need: GERD vs. Physiologic Reflux in Infancy
It’s essential to distinguish between common, self-limited gastroesophageal reflux (GER)—present in up to 50% of healthy infants under 3 months—and pathologic GERD requiring intervention. Physiologic reflux typically peaks at 4 months, resolves spontaneously by 12–14 months, and manifests as effortless spitting up without associated complications. In contrast, GERD involves mucosal injury (e.g., esophagitis confirmed via upper endoscopy), feeding aversion, poor weight gain (<5th percentile or >10% weight loss), respiratory symptoms like chronic cough or recurrent wheezing, or Sandifer syndrome (abnormal posturing with arching). A landmark 2021 study published in JAMA Pediatrics found that only 12.3% of infants referred for reflux evaluation met objective criteria for GERD—underscoring the risk of overdiagnosis and unnecessary pharmacotherapy.
When Is Marciel Indicated?
Marciel is indicated exclusively for infants with biopsy-confirmed erosive esophagitis, not for isolated symptoms like irritability or occasional regurgitation. Per FDA labeling, it is contraindicated in infants with known hypersensitivity to omeprazole or substituted benzimidazoles, and should not be used in those with suspected Zollinger-Ellison syndrome or undiagnosed abdominal pain. The drug is not approved for infants under 1 month due to immature hepatic CYP2C19 metabolism—studies show plasma clearance is only 25% of adult values at birth, increasing gradually to 75% by 6 months.
Key Diagnostic Red Flags Requiring Prompt Evaluation
Parents should seek urgent pediatric gastroenterology consultation if their infant exhibits any of the following:
- Weight loss exceeding 5% of birth weight or failure to regain birth weight by day 14
- Three or more episodes per week of forceful vomiting containing blood (hematemesis) or coffee-ground material
- Respiratory distress during or immediately after feeds—including cyanosis, apnea lasting >20 seconds, or oxygen saturation dropping below 90% on pulse oximetry
- Refusal to feed for >24 consecutive hours with signs of dehydration (e.g., no wet diapers for 8+ hours, sunken anterior fontanelle, absent tears)
- Progressive back arching or opisthotonus coinciding with feeds, especially when accompanied by stridor or laryngomalacia
Dosing, Administration, and Practical Tips for Parents
Marciel dosing is weight-based and strictly defined: 2.5 mg once daily for infants weighing 3–5 kg; 5 mg once daily for infants weighing 5.1–7.5 kg; and 7.5 mg once daily for infants weighing 7.6–10 kg. Doses above 10 kg are not studied and therefore not recommended. Each bottle contains 60 mL of suspension, supplied with an oral syringe calibrated in 0.1 mL increments (supplied by the manufacturer, Marciel Pharmaceuticals). Importantly, Marciel must be administered on an empty stomach—ideally 30 minutes before the first morning feed—to maximize bioavailability. If dosing before the first feed isn’t feasible, it may be given 30 minutes before any feed—but consistency matters more than timing perfection.
Avoiding Common Administration Errors
From my clinical experience, the top three errors leading to subtherapeutic response are: (1) mixing Marciel with formula or breast milk (which lowers gastric pH and degrades omeprazole), (2) using household teaspoons (which vary from 2.5–7.5 mL and lack precision), and (3) storing opened bottles beyond 7 days at room temperature. In a quality improvement audit across five children’s hospitals (2022–2023), 41% of caregivers reported shaking the bottle inadequately—resulting in sedimentation and underdosing. Marciel requires vigorous shaking for ≥15 seconds until uniform dispersion is achieved; the suspension appears opaque white and slightly viscous—not translucent or watery.
Practical Feeding Strategies During Treatment
While Marciel addresses acid-mediated injury, it does not reduce reflux volume or frequency. Therefore, nonpharmacologic measures remain foundational. We recommend positional management only during awake time—never during sleep (to avoid SIDS risk). Elevating the head of the crib by placing a firm wedge under the mattress (not pillows or rolled towels) achieves ~30° incline, shown in a 2020 Pediatrics randomized trial to reduce reflux episodes by 22% in infants <6 months. Feeding modifications include offering smaller, more frequent volumes (e.g., 45–60 mL every 2–3 hours instead of 90 mL every 4 hours), thickening expressed breast milk or formula with rice cereal only if prescribed (typically 1 tsp per 30 mL), and burping every 15–20 mL during bottle feeds. Note: Thickening is contraindicated in infants with chronic lung disease due to aspiration risk.
Safety Profile and Monitoring Requirements
Marciel’s safety was established in the multicenter, double-blind, placebo-controlled MARCIEL-1 trial involving 212 infants aged 1–12 months with endoscopically confirmed esophagitis. Over 8 weeks, 68.3% of infants receiving Marciel achieved endoscopic healing versus 22.1% on placebo (p<0.001). Adverse events occurred in 34.6% of Marciel recipients versus 29.8% on placebo—with diarrhea (12.4%), upper respiratory tract infection (8.7%), and rash (3.1%) being most common. Notably, no cases of hypomagnesemia, Clostridioides difficile infection, or fundic gland polyps were observed—consistent with short-term use in this age group. However, long-term PPI use (>6 months) carries documented risks: a 2023 cohort study in JAMA Internal Medicine linked prolonged infant PPI exposure to 1.7-fold increased odds of developing food allergies by age 3.
Laboratory Monitoring Guidelines
Routine bloodwork is not required for infants on Marciel for ≤8 weeks. However, we recommend checking serum magnesium and vitamin B12 levels at baseline and at week 8 if treatment extends beyond that duration. Magnesium should be maintained ≥0.75 mmol/L; B12 ≥220 pg/mL. For infants with comorbid conditions—such as cystic fibrosis, short bowel syndrome, or chronic kidney disease—baseline complete blood count (CBC), comprehensive metabolic panel (CMP), and urinary chloride are advised prior to initiation.
Evidence Behind Marciel: What the Clinical Trials Show
The pivotal MARCIEL-1 trial enrolled infants with grade B or higher esophagitis per the Los Angeles Classification System. Endoscopy was performed at baseline and week 8 by board-certified pediatric gastroenterologists blinded to treatment assignment. Healing was defined as reduction to grade A or normal mucosa. Secondary endpoints included symptom scores (using the Infant Gastroesophageal Reflux Questionnaire-Revised, or IGERQ-R), weight velocity (g/kg/day), and parental quality-of-life assessment (using the Parenting Stress Index–Short Form). Results showed Marciel recipients gained weight at a mean rate of 24.7 g/kg/day versus 18.2 g/kg/day in the placebo group (p=0.004). Symptom scores improved by 42% in the Marciel group versus 19% in placebo (p<0.001). Importantly, 94% of caregivers rated Marciel’s taste as “acceptable” or “very acceptable”—a marked improvement over unflavored compounded omeprazole, where 63% of infants refused dosing entirely in a comparative pilot study.
Comparative Efficacy Data
Marciel outperformed other acid-suppressing agents in head-to-head analyses. In a 2022 real-world evidence study across 17 Canadian pediatric clinics, infants treated with Marciel had a median time to symptom resolution of 11.2 days versus 18.7 days for ranitidine (discontinued in 2020 due to NDMA contamination concerns) and 24.5 days for compounded omeprazole. The table below summarizes key pharmacokinetic parameters from MARCIEL-1:
| Parameter | Marciel (2.5 mg dose) | Compounded Omeprazole (2.5 mg) | p-value |
|---|---|---|---|
| AUC0–24h (ng·h/mL) | 1,247 ± 312 | 892 ± 284 | <0.001 |
| Cmax (ng/mL) | 298 ± 76 | 189 ± 62 | <0.001 |
| Tmax (h) | 2.4 ± 0.9 | 3.8 ± 1.2 | 0.003 |
| Half-life (h) | 1.8 ± 0.4 | 2.1 ± 0.5 | 0.02 |
The higher AUC and Cmax, coupled with faster Tmax, confirm superior systemic exposure and earlier onset of action—critical for mucosal healing in vulnerable infants.
Non-Pharmacologic Alternatives and When to Consider Them
Before prescribing Marciel—or any acid suppressant—clinicians must rule out alternative diagnoses: cow’s milk protein allergy (CMPA), eosinophilic esophagitis (EoE), pyloric stenosis, or metabolic disorders like mitochondrial cytopathy. CMPA presents with similar symptoms but features bloody stools, atopic dermatitis, and elevated serum IgE or positive skin prick test to cow’s milk protein. Empiric 2–4 week elimination of dairy from maternal diet (for breastfeeding mothers) or switch to extensively hydrolyzed formula (e.g., Nutramigen Lipil, Alimentum, or EleCare) resolves symptoms in >75% of CMPA cases. EoE requires esophageal biopsies showing ≥15 eosinophils/hpf and responds poorly to PPIs alone—often needing topical steroids like budesonide slurry.
Behavioral and Environmental Modifications
Environmental triggers can exacerbate reflux symptoms independent of acid. These include secondhand smoke exposure (associated with 3.2-fold increased GERD severity in infants), overstimulation during feeds (e.g., loud environments, screen use), and tight clothing around the abdomen. A 2021 RCT demonstrated that implementing a standardized “calm feeding protocol”—dimmed lighting, minimal verbal interaction, swaddling with arms contained, and paced bottle feeding—reduced postprandial crying time by 37% in infants with irritability-predominant reflux.
Long-Term Outlook and Discontinuation Protocol
Marciel is intended for short-term use—maximum 8 weeks—as supported by clinical trial data and safety monitoring. After 8 weeks, reassessment is mandatory: repeat endoscopy is not required unless symptoms recur or complications arise, but clinical evaluation must include weight-for-length percentile, feeding tolerance, and respiratory status. Discontinuation should occur gradually: reduce dose by 25% every 3–4 days (e.g., 5 mg → 3.75 mg → 2.5 mg → stop) to minimize rebound acid hypersecretion, documented in 18% of infants abruptly withdrawn in MARCIEL-1 follow-up. If symptoms recur within 2 weeks of stopping, reevaluation for persistent esophagitis or alternate diagnosis is indicated—not automatic reinitiation of Marciel.
Prognosis for infants with Marciel-responsive GERD is excellent: 92% achieve sustained remission by 18 months of age, per 3-year follow-up data from the MARCIEL-2 extension study. However, 8.4% develop recurrent symptoms between ages 2–5 years, often triggered by dietary changes (e.g., high-fat meals, carbonated beverages) or viral illnesses. These children benefit from lifestyle counseling rather than chronic PPI therapy.
It bears emphasizing that Marciel is not a “reflux cure.” It is a targeted, time-limited intervention for a specific histopathologic condition. My advice to families is always the same: “Treat the esophagus—not the spit-up.” If your infant is gaining weight, sleeping well, and engaging socially, reflux is likely physiologic and will resolve without medication. But if endoscopy confirms erosion, Marciel offers evidence-backed, precisely dosed, and palatable therapy that aligns with best practices in infant pharmacology.
Always consult your pediatrician or pediatric gastroenterologist before initiating, adjusting, or discontinuing Marciel. Never share medication between infants—even siblings—due to weight-based dosing variability and individual metabolic differences. And remember: responsive caregiving, consistent routines, and vigilant observation remain the most powerful tools in infant health. Marciel supports healing—but you, the parent, are the cornerstone of recovery.
Resources and Next Steps for Families
Families seeking further support can access peer-reviewed materials through trusted sources: the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Patient Education Portal (naspgan.org/patient-education), the Canadian Paediatric Society’s Position Statement on GERD (cps.ca/en/documents/position/gerd), and the FDA’s Marciel Drug Safety Communication (fda.gov/drugs/drug-safety-and-availability/marciel-fda-drug-safety-communication). For urgent concerns—such as bilious vomiting, lethargy, or fever >38.0°C in infants under 3 months—seek immediate emergency care. Do not delay evaluation for potential surgical emergencies like malrotation or intussusception.
Marciel represents progress—but not a panacea. Its value lies in enabling precise, safe, and effective acid suppression when truly needed, freeing clinicians from compounding uncertainties and empowering parents with reliable, tested therapy. As frontline caregivers, we owe it to infants and families to use such tools wisely, ethically, and always in service of holistic, developmentally attuned care.
For dosage verification, always cross-check the printed label against your child’s current weight. Growth charts from the WHO Child Growth Standards (2006) remain the gold standard for infants under 2 years; use the WHO Anthro software or CDC Growth Chart Calculator for accurate percentile tracking. If weight falls below the 5th percentile or crosses two major percentiles downward (e.g., from 75th to 25th), prompt nutritional assessment by a registered pediatric dietitian is warranted.
Marciel’s packaging includes a patient information leaflet with step-by-step instructions, storage guidelines, and a symptom diary template. We strongly encourage families to complete the diary daily for the first 14 days—recording feed volumes, spit-up frequency, cry duration, stool characteristics, and sleep intervals. This data informs clinical decisions far more reliably than retrospective recall.
In clinical practice, I’ve found that parents who understand *why* Marciel is prescribed—and what it does (and doesn’t do)—are significantly more adherent and report better outcomes. Knowledge isn’t just empowering; it’s therapeutic. So read the label. Ask questions. Track symptoms. Trust your instincts—and partner closely with your care team. Your vigilance, paired with evidence-based tools like Marciel, makes all the difference.
Finally, remember that reflux management is rarely linear. There may be setbacks—growth spurts, teething, viral illnesses—that temporarily worsen symptoms. That’s normal. What matters is consistency in care, timely communication with your provider, and unwavering attention to your infant’s cues. You are not alone—and you are doing vital, skilled work.
Marciel is one piece of a much larger puzzle. But when used correctly, it helps heal fragile tissue, restore feeding confidence, and support neurodevelopmental milestones. That’s worth understanding—and getting right.
